Status:
NOT_YET_RECRUITING
Cross-validation of a Predictive Model of Response to Anti-TNF Alpha Based on Oxylipin Response in Rheumatoid Arthritis
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Unité de Nutrition Humaine, INRAE, Centre Auvergne-Rhône Alpes
Immunology department, CHU Clermont-Ferrand
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to use a blood test to predict whether a participant diagnosed with rheumatoid arthritis will respond to anti-TNF alpha treatment . The main questions it aims to ans...
Eligibility Criteria
Inclusion
- Male or female patient aged 18 years or older with rheumatoid arthritis according to ACR EULAR 2010 criteria
- Active disease as defined by DAS-28-CRP\>3.2
- Naive to targeted biologic or synthetic therapy
- Rheumatologist's decision to start anti-TNFα treatment
- Stable corticosteroid therapy ≤ 10 mg/day
- Patient enrolled in or benefiting from a social security scheme
- Patient who has given written informed consent to participate in the study
Exclusion
- Contraindication to biological treatment (cancer or history of cancer)
- Treatment with non-steroidal anti-inflammatory drugs in the 2 weeks prior to enrolment
- Protected persons (pregnant and/or breastfeeding women, persons under guardianship or conservatorship)
Key Trial Info
Start Date :
March 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06880146
Start Date
March 15 2025
End Date
November 1 2027
Last Update
March 17 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63000
2
Hopital Cochin, APHP
Paris, France, 75014
3
CHU Saint Etienne
Saint-Etienne, France, 42055